These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20087177)

  • 1. Induction therapy in acute myeloid leukemia: intensifying and targeting the approach.
    Fernandez HF; Rowe JM
    Curr Opin Hematol; 2010 Mar; 17(2):79-84. PubMed ID: 20087177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups.
    Amadori S; Suciu S; Willemze R; Mandelli F; Selleslag D; Stauder R; Ho A; Denzlinger C; Leone G; Fabris P; Muus P; Vignetti M; Hagemeijer A; Beeldens F; Anak O; De Witte T; ;
    Haematologica; 2004 Aug; 89(8):950-6. PubMed ID: 15339678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
    Leopold LH; Berger MS; Cheng SC; Cortes-Franco JE; Giles FJ; Estey EH
    Clin Adv Hematol Oncol; 2003 Apr; 1(4):220-5. PubMed ID: 16224410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
    Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
    Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents.
    Tallman MS
    Hematology Am Soc Hematol Educ Program; 2005; ():143-50. PubMed ID: 16304372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia patients].
    Sakamaki H
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1629-34. PubMed ID: 18799927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination chemotherapy for acute myeloid leukemia].
    Nagai T
    Nihon Rinsho; 2009 Oct; 67(10):1921-5. PubMed ID: 19860191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a role for intensifying induction therapy in acute myeloid leukaemia (AML)?
    Rowe JM
    Best Pract Res Clin Haematol; 2009 Dec; 22(4):509-15. PubMed ID: 19959101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older.
    Eom KS; Kim HJ; Min WS; Lee S; Min CK; Cho BS; Kim SY; Kim YJ; Lee DG; Choi SM; Cho SG; Kim DW; Lee JW; Shin WS; Kim CC
    Eur J Haematol; 2007 Nov; 79(5):398-404. PubMed ID: 17916082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New trends in the standard of care for initial therapy of acute myeloid leukemia.
    Fernandez HF
    Hematology Am Soc Hematol Educ Program; 2010; 2010():56-61. PubMed ID: 21239771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensorimotor peripheral neuropathy in an elderly AML patient in complete remission while receiving gemtuzumab ozogamicin as maintenance therapy.
    Romani C; Murru R; Adamo F; Di Tucci A; Sabiu D; Casula P; Angelucci E
    Ann Hematol; 2006 Jun; 85(6):411-2. PubMed ID: 16538500
    [No Abstract]   [Full Text] [Related]  

  • 14. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
    Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemtuzumab ozogamicin as first-line treatment in patients aged 70 years or older with acute myeloid leukemia.
    McHayleh W; Foon K; Redner R; Sehgal R; Raptis A; Agha M; Luong TM; Schlesselman JJ; Boyiadzis M
    Cancer; 2010 Jun; 116(12):3001-5. PubMed ID: 20564405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody therapy for acute myeloid leukemia.
    Mulford D
    Semin Hematol; 2008 Apr; 45(2):104-9. PubMed ID: 18381105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
    Stasi R; Evangelista ML; Buccisano F; Venditti A; Amadori S
    Cancer Treat Rev; 2008 Feb; 34(1):49-60. PubMed ID: 17942233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How can one optimize induction therapy in AML?
    Luger SM
    Best Pract Res Clin Haematol; 2017 Dec; 30(4):301-305. PubMed ID: 29156199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New drugs in acute myeloid leukemia.
    Estey E
    Semin Oncol; 2008 Aug; 35(4):439-48. PubMed ID: 18692694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
    Martin MG; Augustin KM; Uy GL; Welch JS; Hladnik L; Goyal S; Tiwari D; Monahan RS; Reichley RM; Cashen AF; Stockerl-Goldstein K; Westervelt P; Abboud CN; Dipersio JF; Vij R
    Am J Hematol; 2009 Nov; 84(11):733-7. PubMed ID: 19806665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.